Amphastar Pharmaceuticals, Inc. (AMPH) Operating Margin
- Operating margin · 12 months: Value 15.66%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 15.66% | Operating income / revenue. Period ending 2026-06-30. $114.28M ÷ $730.02M × 100 ≈ 15.66% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 114.28M USD | Operating Income (Loss) |
| Revenue | 730.02M USD | |
| Cost of products and services | (m) | |
| Research and development | 94.57M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $114.28M | $730.02M | (m) | $94.57M | (m) | 15.66% |
| 2026-03-31 | $116.74M | $720.53M | (m) | $92.48M | (m) | 16.20% |
| 2025-12-31 | $140.40M | $719.89M | (m) | $85.84M | (m) | 19.50% |
| 2025-09-30 | $149.94M | $723.30M | (m) | $80.67M | (m) | 20.73% |
| 2025-06-30 | $181.67M | $722.68M | (m) | $79.39M | (m) | 25.14% |
| 2025-03-31 | $194.70M | $730.66M | (m) | $76.97M | (m) | 26.65% |
| 2024-12-31 | $205.42M | $731.97M | (m) | $73.91M | (m) | 28.06% |
| 2024-09-30 | $214.25M | $723.55M | (m) | $76.19M | (m) | 29.61% |
| 2024-06-30 | $229.88M | $712.89M | (m) | $71.78M | (m) | 32.25% |
| 2024-03-31 | $211.56M | $676.21M | (m) | $70.97M | (m) | 31.29% |
| 2023-12-31 | $196.99M | $644.39M | (m) | $73.74M | (m) | 30.57% |
| 2023-09-30 | $180.84M | $601.31M | (m) | $70.56M | (m) | 30.07% |
| 2023-06-30 | $131.39M | $540.89M | (m) | $72.41M | (m) | 24.29% |
| 2023-03-31 | $119.32M | $518.64M | (m) | $78.36M | (m) | 23.01% |
| 2022-12-31 | $107.50M | $498.99M | (m) | $74.77M | (m) | 21.54% |
| 2022-09-30 | $93.92M | $484.85M | (m) | $74.82M | (m) | 19.37% |
| 2022-06-30 | $95.46M | $476.92M | (m) | $67.07M | (m) | 20.02% |
| 2022-03-31 | $81.19M | $455.12M | (m) | $62.39M | (m) | 17.84% |
| 2021-12-31 | $69.89M | $437.77M | (m) | $60.93M | (m) | 15.96% |
| 2021-09-30 | $48.51M | $412.80M | (m) | $61.78M | (m) | 11.75% |
| 2021-06-30 | $27.26M | $384.04M | (m) | $68.66M | (m) | 7.10% |
| 2021-03-31 | $13.78M | $368.18M | (m) | $66.69M | (m) | 3.74% |
| 2020-12-31 | $10.95M | $349.85M | (m) | $67.23M | (m) | 3.13% |
| 2020-09-30 | $7.83M | $337.31M | (m) | $68.74M | (m) | 2.32% |
| 2020-06-30 | $6.72M | $334.01M | (m) | $69.70M | (m) | 2.01% |
| 2020-03-31 | $10.61M | $327.25M | (m) | $69.55M | (m) | 3.24% |
| 2019-12-31 | $-39.00K | $322.36M | (m) | $68.85M | (m) | -0.01% |
| 2019-09-30 | $1.75M | $328.66M | (m) | $65.94M | (m) | 0.53% |
| 2019-06-30 | $1.90M | $324.07M | (m) | $58.68M | (m) | 0.59% |
| 2019-03-31 | $-2.02M | $316.06M | (m) | $58.14M | (m) | -0.64% |
| 2018-12-31 | $-8.62M | $294.67M | (m) | $57.56M | (m) | -2.93% |
| 2018-09-30 | $-11.54M | $265.38M | (m) | $52.13M | (m) | -4.35% |
| 2018-06-30 | $-17.26M | $247.75M | (m) | $51.16M | (m) | -6.97% |
| 2018-03-31 | $-12.22M | $241.90M | (m) | $46.42M | (m) | -5.05% |
| 2017-12-31 | $-895.00K | $240.18M | (m) | $43.41M | (m) | -0.37% |
| 2017-09-30 | $-3.74M | $243.32M | (m) | $44.30M | (m) | -1.54% |
| 2017-06-30 | $4.88M | $249.62M | (m) | $43.98M | (m) | 1.95% |
| 2017-03-31 | $13.02M | $252.47M | (m) | $43.84M | (m) | 5.16% |
| 2016-12-31 | $15.69M | $255.16M | (m) | $41.20M | (m) | 6.15% |
| 2016-09-30 | $34.57M | $268.53M | (m) | $37.24M | (m) | 12.87% |
| 2016-06-30 | $25.03M | $268.18M | (m) | $38.64M | (m) | 9.33% |
| 2016-03-31 | $4.44M | $254.00M | (m) | $38.88M | (m) | 1.75% |
| 2015-12-31 | $-6.90M | $251.52M | (m) | $37.06M | (m) | -2.74% |
| 2015-09-30 | $-28.29M | $230.48M | (m) | $36.05M | (m) | -12.28% |
| 2015-06-30 | $-32.36M | $226.33M | (m) | $33.52M | (m) | -14.30% |
| 2015-03-31 | $-23.27M | $221.48M | (m) | $28.79M | (m) | -10.51% |
| 2014-12-31 | $-17.98M | $210.46M | (m) | $28.43M | (m) | -8.54% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $222.59M | (m) | (m) | (m) | (m) |
| 2013-12-31 | $17.49M | $229.68M | (m) | $33.02M | (m) | 7.61% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $25.40M | $204.32M | (m) | $31.16M | (m) | 12.43% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |